Sentences with phrase «of changes in the programming»

The AHCA would have switched Medicaid to block grants, which means states would receive a fixed amount of federal funding each year regardless of changes in program enrollment and mandates.

He responded to director questions on costs and effectiveness of various programs, actions being taken to train staff and plans to make constituents aware of changes in the programming.

Skill in the application of methods and techniques (e.g., cost - benefit analysis, amortization, depreciation, and prorating revenues and costs among customers) to analyze and evaluate the effects of changes in program plans and funding.

This takes an immense weight off his clients» shoulders and makes them feel provided for by not only Schupp, but HSA's skilled and communicative sales reps. Schupp's local HSA rep, Kristen Moore, keeps his team informed of changes in the program or plans, and helps him better explain the warranty process to his clients and customers.

Not exact matches

The real significance of the Google Patent Starter Program is instead more subtle, and should be seen against the backdrop of other moves Google is undertaking to change the economic incentives that have made patents such a problem for the tech sector in the first place.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

«Major tax increases or policy changes such as big hikes in the minimum wage will probably do more harm than good,» says Dahlby of the sort of programs necessary to satisfy vocal public - health boards.

Perhaps in recognition of this reality, the medical program is about to change in a way that could lead to a boom in licensed dealers and smokers.

To be the most successful Defy Ventures graduate in the history of the program so I can employ the most number of Defy graduates and give back to this community that has literally changed my life.

It's running a program for employers, of which about 60 have signed on so far, called 100 % Talent, to help them uncover gaps in pay and in opportunity, and to make changes where necessary.

«In our 14 years in business we have never launched a program that changed the face and direction of the company more significantly than our free POS initiative.&raquIn our 14 years in business we have never launched a program that changed the face and direction of the company more significantly than our free POS initiative.&raquin business we have never launched a program that changed the face and direction of the company more significantly than our free POS initiative.»

In particular, the way that social programs are communicated and the emerging emphasis on the measurement and evaluation of social change.

Originally announced in December by Immigration Minister Jason Kenney, the changes to Canada's Federal Skilled Worker Program aim to improve the economic suitability of new Canadians.

The changes, and the culture of regular reinvention that enabled them, earned platinum status in Deloitte's Canada's Best - Managed Companies program, a recognition given to firms with seven or more years on the list.

«This is a year of really being an influence and a change maker in an amazing city that's really at the forefront of the revitalization efforts in our entire country,» says Greene Groves concluding her pitch for the program, ending with a paraphrase of the Michigan governor's pitch for Motor City: «Yeah, you can go to another city, but if you want to make a difference, come to Detroit.»

Michael Pehl of i - Cube has developed a program that rewards employees in ongoing quarterly and annual campaigns with progressive and changing incentives.

Icahn owns an 82 % stake in CVR Energy, which along with other refining companies, has called for changes to the Renewable Fuel Program to shift the burden of blending biofuels into gasoline away from refiners and further down stream to marketers.

For those looking for a deep dive into the subject, there are long lists of skills to acquire or outlines of multistep training programs to follow, but if you're more interested in simple but powerful changes that you can make today, a recent post on blog Dumb Little Man is for you.

«A mystery shopping program in and of itself does not change behaviors,» says Warzynski.

«We're now in a position where we need to make changes to the Scene program,» said Pat Marshall, Cineplex's vice-president of communications and investor relations.

Be sure to provide your cultural change program communication in a variety of ways to improve understanding and acceptance among your people.

To that end, we have teamed up with the University of North Carolina's Kenan - Flagler Business School — a recognized leader in online business education — to create an innovative executive certificate program called: Change the World: Leading with Purpose.

These forward - looking statements include, among other things, statements about full - year 2018 guidance, project milestones, increased opportunities in the market, backlog, bids and change orders outstanding, target projects and revenue opportunity pipeline, to the extent these may be viewed as indicators of future revenues or profitability, the expected impacts of the F2G program and progress toward completing the proposed combination with CB&I and the anticipated benefits of that transaction.

There's an element of psychology at work here in that when we encounter crisis in our lives, we're also programmed to deal with change in a way that, in more normal times when everything seems fine, we tend to reject.

This weekend pays tribute to a specific era, 1985 - 89, and features a host of initiatives like cars with old - school car paint schemes, commemorative ticket and program designs, specially - designed apparel, retro food offerings at the track... unlike, say, baseball or football throw - back games where the only real change is the team's uniforms, Darlington and its partners goes all in.

The Boy Scouts of America is changing the name of its program for older youth — the Boy Scouts — to Scouts BSA in February 2019, a move that reflects its decision to include young women.

The settlement also stipulates that the San Diego - based chip maker implement policy changes and programs to better promote female employees working in the field of science, technology, engineering and mathematics, known as STEM.

In the heat of the battle for ratings and students, the traditional programs are making changes.

Pharmaceutical companies are concerned about an onslaught of legislative proposals percolating in state houses around the country, among them: changes to Medicaid programs to rein in the high cost of prescription drugs, intellectual property issues, and the fight over biosimilars.

«But all it takes is a couple of dedicated teachers with a little support and guidance to run important research programs that can produce winners in this competition and more importantly kids who are going to go on to become scientists and change the world.»

In a separate TriNet survey, 76 percent of respondents said proposed changes to that program would have a negative impact on their companies.

The Disney CEO also noted that 83 % of all multichannel households turned to ESPN in the first quarter of this year, and that 96 % of all sports programming is watched live, which he called «particularly valuable in today's rapidly changing advertising marketplace.»

Secondly, there could be changes to the Optional Practical Training program, which gives foreign graduates from U.S. colleges in science and tech an additional two years of work authorization.

For those looking to make a change in their health in 2017, it may be worth considering a more mindful fitness program, as they have the potential to make you one of the 8 % of people who actually achieve their resolution goals.

Jason Hollett, the Environment Department's executive director of climate change, said Nova Scotia's program would cover 80 to 90 per cent of all emissions in the province.

Bledsoe, at the University of Georgia, said there's no need to wait for big changes in the program to start making progress.

While many organizations have invested more resources in better training their customer service representatives, the recent wave of artificial intelligence (AI) programming is changing the name of the game, mainly through robotic messaging capabilities — a.k.a, chatbots.

Regulatory changes had been in the wind for some time as the evidence against the program built up, yet employers relied on the lobbying efforts of the Canadian Federation of Independent Business to maintain the program rather than taking steps to improve domestic recruitment and training efforts or adjust wages and benefits to attract workers.

In addition, Alaska Air still needs to rebrand all of the Virgin America planes, change their interiors and bring the two airlines» loyalty programs together.

Many a desktop computer has been purchased specifically to take advantage of these programs, which allow even an unsophisticated computer user to change a few critical assumptions and, in the blink of an eye, recalculate an entire financial model (see «How VisiCalc Works,» INC., November 1981, page 104).

The federal government announced initial changes in April, scrapping an aspect of the program that allowed employers to pay foreign workers as much as 15 per cent less than the average wage for a job.

Michael Hostetter, director of Boeing Co's Vertical Lift Programs in Germany, told Reuters the change was good news for Boeing, the largest U.S. exporter.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

While the preferences of millennials are changing, requiring entrepreneurs to examine brand loyalty in an entirely new way, retailers can still drive return sales by creating a transparent and value - added loyalty program.

But in a new e-book coauthored with Ross Walker, a 2005 graduate of Stanford's MBA program, they argue that networking ability is not just important for career success — «it is also crucial for getting things accomplished and making change inside organizations in both the public and private sector.»

«In order to accelerate meaningful corporate and market impact, many corporations are expanding their CVC unit mandates to include traditional minority investments, majority equity investment more consistent with Growth PE, M&A and internal commercial piloting and incubation programs; and compensation structures need to keep pace with these changes,» said Heidi Mason, managing partner of Bell Mason Group and co-founder of CVI ².

Points expiration / losing points: Your points don't expire as long as your account remains open, however, you will immediately lose all your points if your account status changes, or your account is closed for program misuse, fraudulent activities, failure to pay, bankruptcy, or other reasons described in the terms of the Rewards Program Agrprogram misuse, fraudulent activities, failure to pay, bankruptcy, or other reasons described in the terms of the Rewards Program AgrProgram Agreement.

You may recall that on last quarter's call, we cautioned that the launch of the new Rewards program could result in some noise in our comp figures as customers and partners adapted to the program changes.

From what we see coming out of the top levels of China's leadership in the past few weeks, we should be reasonably encouraged that some of the targets of these complaints are programmed for change.

«We do nt foresee the ECB making any changes at all until September, when the QE program officially ends,» said Alfonso Esparza, senior currency strategist at Oanda Corporation in Toronto, Canada, referring to the bank's purchases of bonds.